Effect of shRNA‑mediated knockdown of vascular endothelial growth factor on the proliferation of choroid‑retinal endothelial cells under hypoxic conditions

Liu,Ai‑Hua; Sun,Jing; Shi,Yi; Sun,Guo‑Ling; Zhang,Hong

doi:10.3892/etm.2015.2596

Effect of shRNA‑mediated knockdown of vascular endothelial growth factor on the proliferation of choroid‑retinal endothelial cells under hypoxic conditions

Authors:
- Ai‑Hua Liu
- Jing Sun
- Yi Shi
- Guo‑Ling Sun
- Hong Zhang
View Affiliations

Affiliations: Department of Glaucoma and Fundus Diseases, Tianjin Medical University Eye Hospital, Tianjin 300384, P.R. China
Published online on: June 25, 2015 https://doi.org/10.3892/etm.2015.2596
Pages: 1019-1024

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of vascular endothelial growth factor (VEGF) in cell proliferation under hypoxic conditions. Gene knockdown of VEGF was conducted in the choroid‑retinal endothelial RF/6A cell line by transfection with short hairpin RNA (shRNA), in which a shRNA fragment against VEGF was synthesized and cloned into the vector, pSilencer 2.1‑U6 neo. Subsequently, a model of hypoxia was established in the RF/6A cell line via treatment with CoCl2, into which the recombinant plasmids, containing the VEGF‑targeting shRNA (p‑shRNA), were transfected. The study included four treatment groups, namely a control group (normal group), a hypoxia group treated with CoCl2 (CoCl2 group), a control plasmid group that were subjected to CoCl2 treatment and transfection with a pSilencer 2.1‑U6 neo plasmid without the shRNA (CoCl2 + p‑NC group), and a group treated with CoCl2 and transfected with a pSilencer 2.1‑U6 neo plasmid containing the VEGF‑targeting shRNA (CoCl2 + p‑shRNA group). Subsequent to treatment, the mRNA and protein expression levels of VEGF were evaluated using quantitative polymerase chain reaction and western blot analysis, respectively, In addition, cell proliferation was assessed. RF/6A cells treated with CoCl2 reduced cell connectivity, irregular morphology and reduced thickness compared with the cells in the normal group. However, cells in the CoCl2 + p‑shRNA group exhibited an improved morphology compared with the CoCl2 and CoCl2 + p‑NC groups. Cell proliferation in the CoCl2 group was enhanced in a time‑dependent manner. However, the hypoxia‑induced increase in cell proliferation was significantly inhibited in the CoCl2 + p‑shRNA group, with inhibition rates of 16, 32 and 38% at 24, 48 and 72 h, respectively. The mRNA and protein expression levels of VEGF were increased in the CoCl2 group when compared with the normal group, and these hypoxia‑induced increases in VEGF expression were reduced in the CoCl2 + p‑shRNA group. Therefore, the results indicated that the targeted knockdown of VEGF in vascular endothelial cells may be effective for the treatment of retinal neovascularization diseases.

View Figures

View References

1	Heldin CH: Development possible clinical use of antagonists for PDGF and TGF-beta. Ups J Med Sci. 109:165–178. 2004. View Article : Google Scholar : PubMed/NCBI
2	Lee YM, Bae MH, Lee OH, et al: Synergistic induction of in vivo angiogenesis by the combination of insulin-like growth factor-II and epidermal growth factor. Oncol Rep. 12:843–848. 2004.PubMed/NCBI
3	Cantón A, Burgos R, Hernández C, et al: Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Br J Ophthalmol. 84:732–735. 2000. View Article : Google Scholar : PubMed/NCBI
4	Du S, Wang S, Wu Q, Hu J and Li T: Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells. Exp Eye Res. 116:151–160. 2013. View Article : Google Scholar : PubMed/NCBI
5	Frank RN: Diabetic retinopathy. N Engl J Med. 350:48–58. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ozaki H, Yu AY, Della N, et al: Hypoxia inducible factor-1 alpha is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 40:182–189. 1999.PubMed/NCBI
7	Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10:145–147. 2004. View Article : Google Scholar : PubMed/NCBI
8	Gragoudas ES, Adamis AP, Cunningham et Jr, et al: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 351:2805–2816. 2004. View Article : Google Scholar : PubMed/NCBI
9	Mongerard-Coulanges M, Migianu-Griffoni E, Lecouvey M and Jolles B: Impact of alendronate and VEGF-antisense combined treatment on highly VEGF-expressing A431 cells. Biochem Pharmacol. 77:1580–1585. 2009. View Article : Google Scholar : PubMed/NCBI
10	Shuey DJ, MeCallus DE and Giordano T: RNAi: Gene-silencing in therapeutic intervention. Drug Discov Today. 7:1040–1046. 2002. View Article : Google Scholar : PubMed/NCBI
11	Aravin AA, Klenov MS, Vagin VV, Rozovskiĭ IaM and Gvozdev VA: Role of double-stranded RNA in eukaryotic gene silencing. Mol Biol (Mosk). 36:240–251. 2002.(In Russian). View Article : Google Scholar : PubMed/NCBI
12	Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hanh WC, Sharp PA, et al: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 9:493–501. 2003. View Article : Google Scholar : PubMed/NCBI
13	Itakura J, Ishiwata T, Shen B, Kornmann M and Korc M: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 85:27–34. 2000. View Article : Google Scholar : PubMed/NCBI
14	Sharkey AM, Day K, Mcpherson A, Malik S, Licence D, Smith SK and Charnock-Jones DS: Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. J Clin Endocrinol Metab. 85:402–409. 2000. View Article : Google Scholar : PubMed/NCBI
15	Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992. View Article : Google Scholar : PubMed/NCBI
16	Klagsburn M and D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7:259–270. 1996. View Article : Google Scholar : PubMed/NCBI
17	Elahy M, Baindur-Hudson S, Newsholme P and Dass C: Mechanisms of PEDF mediated protection against ROS damage in diabetic retinopathy and neuropathy. J Endocrinol. 222:R129–R139. 2014. View Article : Google Scholar : PubMed/NCBI
18	Aiello LP, Northrup JM, Keyt BA, Takagi H and Iwamoto MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 113:1538–1544. 1995. View Article : Google Scholar : PubMed/NCBI
19	Thieme H, Aiello LP, Takagi H, Ferrara N and King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 44:98–103. 1995. View Article : Google Scholar : PubMed/NCBI
20	Song E, Zhu P, Lee SK, et al: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 23:709–717. 2005. View Article : Google Scholar : PubMed/NCBI
21	Jia RB, Fan XQ, Wang XL, Zhang XQ, Zhang P and Lu J: Inhibition of VEGF expression by plasmid-based RNA interference in the retinoblastoma cells. Zhonghua Yan Ke Za Zhi. 43:493–498. 2007.(In Chinese). PubMed/NCBI
22	Wang J, Shi YQ, Yi J, et al: Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. J Dig Dis. 9:228–237. 2008. View Article : Google Scholar : PubMed/NCBI
23	Shen J, Yang X, Xiao WH, Hackett SF, Sato Y and Campochiaro PA: Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J. 20:723–725. 2006.PubMed/NCBI
24	Murata M, Takanmi T, Shimizu S, et al: Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr Eye Res. 31:171–180. 2006. View Article : Google Scholar : PubMed/NCBI
25	Cai CM, Sun BC and Liu XY: Short hairpin RNA targeting vascular endothelial growth factor effectively inhibits expression of vascular endothelial growth factor in human retinal pigment epithelium. Zhonghua Yan Ke Za Zhi. 42:334–337. 2006.(In Chinese). PubMed/NCBI
26	Xia XB, Xiong SQ, Song WT, Luo J, Wang YK and Zhou RR: Inhibition of retinal neovascularization by siRNA targeting VEGF (165). Mol Vis. 14:1965–1973. 2008.PubMed/NCBI